Drug Price Trends for ELIQUIS DVT-PE TREATMENT

Average Pharmacy Cost for ELIQUIS DVT-PE TREATMENT

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	5.50588	EACH	2026-07-22
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	5.50728	EACH	2026-06-17
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	5.50716	EACH	2026-05-20
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	5.51104	EACH	2026-01-01
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	9.66849	EACH	2025-12-17
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	9.66021	EACH	2025-11-19
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK	00003-3764-74	9.65738	EACH	2025-10-22

Market Analysis and Price Projections for ELIQUIS DVT-PE Treatment

Last updated: July 27, 2025

ELIQUIS, also known by its generic name apixaban, has emerged as a leading anticoagulant in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). As we look towards the future, understanding the market dynamics and price projections for this crucial medication becomes increasingly important for healthcare providers, patients, and investors alike.

The Rise of ELIQUIS in the Anticoagulant Market

ELIQUIS, developed by Bristol Myers Squibb and Pfizer, has rapidly gained prominence in the anticoagulant market since its approval for DVT and PE treatment in 2014[6]. Its success can be attributed to several factors:

1. Efficacy: ELIQUIS has shown superior efficacy in reducing the risk of recurrent DVT and PE compared to traditional anticoagulants.

2. Safety profile: The drug offers a favorable safety profile with a lower risk of major bleeding events.

3. Convenience: As an oral medication, ELIQUIS eliminates the need for routine coagulation testing and does not require the use of a parenteral anticoagulant during initiation[6].

These advantages have positioned ELIQUIS as a preferred choice among healthcare providers and patients, contributing to its significant market share.

Current Market Position

As of 2023, the ELIQUIS market size was valued at USD 31.04 Billion[5]. This impressive figure reflects the drug's strong performance and widespread adoption in the treatment of DVT and PE, as well as other indications such as atrial fibrillation.

ELIQUIS Market size was valued at USD 31.04 Billion in 2023 and is projected to reach USD 75.53 Billion by 2031, growing at a CAGR of 9.3% from 2024 to 2031[5].

This projected growth underscores the continued confidence in ELIQUIS as a leading anticoagulant therapy.

Factors Driving Market Growth

Several key factors are expected to drive the growth of the ELIQUIS market in the coming years:

Increasing Prevalence of Venous Thromboembolism

The rising incidence of venous thromboembolism (VTE), which includes both DVT and PE, is a significant driver of ELIQUIS demand. As the global population ages and risk factors such as obesity and sedentary lifestyles become more prevalent, the number of VTE cases is expected to increase, fueling the need for effective anticoagulant therapies like ELIQUIS[4].

Expanding Indications

The potential for ELIQUIS to receive approval for additional indications could further expand its market reach. Ongoing research and clinical trials may uncover new therapeutic applications for the drug, potentially broadening its patient base[5].

Growing Awareness and Diagnosis

Increased awareness of VTE and improved diagnostic capabilities are leading to earlier detection and treatment of DVT and PE. This trend is expected to drive up the number of patients prescribed ELIQUIS in the coming years[5].

Price Projections and Market Forecasts

Understanding the future pricing landscape for ELIQUIS is crucial for stakeholders across the healthcare spectrum. Several projections and market forecasts provide insight into what we can expect:

Short-term Price Adjustments

In the immediate future, the price of ELIQUIS is set to undergo significant changes due to government regulations. As of January 1, 2026, the U.S. Department of Health and Human Services has imposed a "maximum fair price" (MFP) for ELIQUIS:

The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00[2].

This price adjustment will have a substantial impact on the drug's revenue in the U.S. market, particularly for Medicare patients.

Long-term Market Projections

Despite the short-term pricing challenges, long-term projections for the ELIQUIS market remain optimistic:

1. By 2031, the ELIQUIS market is projected to reach USD 75.53 Billion, growing at a CAGR of 9.3% from 2024 to 2031[5].

2. In the broader anticoagulants market, which includes ELIQUIS, forecasts suggest growth from USD 37.08 billion in 2025 to USD 81.16 billion by 2034, with a CAGR of 9.11%[1].

3. Some projections are even more optimistic, with IMARC Group expecting the global anticoagulants market to reach USD 96.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.46% during 2025-2033[3].

These projections indicate sustained growth for ELIQUIS and the anticoagulant market as a whole, despite potential pricing pressures.

Regional Market Dynamics

The market for ELIQUIS varies significantly across different regions, influenced by factors such as healthcare infrastructure, regulatory environments, and disease prevalence:

North America

North America, particularly the United States, represents the largest market for ELIQUIS. The region's high healthcare expenditure and advanced medical infrastructure contribute to strong adoption rates. Projections indicate continued dominance:

The U.S. anticoagulants market size was evaluated at USD 13.89 billion in 2024 and is projected to be worth around USD 34.82 billion by 2034, growing at a CAGR of 9.63% from 2025 to 2034[1].

Europe

Europe represents another significant market for ELIQUIS, with countries like Germany, France, and the UK showing robust adoption rates. The region's aging population and high prevalence of cardiovascular diseases drive demand for anticoagulants[5].

Asia-Pacific

The Asia-Pacific region is expected to witness rapid growth in the ELIQUIS market. Factors such as increasing awareness of cardiovascular diseases, rising disposable incomes, and improving healthcare infrastructure contribute to this growth potential[1].

Competitive Landscape

While ELIQUIS has established itself as a market leader, it faces competition from other anticoagulants:

1. Xarelto (rivaroxaban): Another popular novel oral anticoagulant (NOAC) that competes directly with ELIQUIS.

2. Traditional anticoagulants: Warfarin and heparin continue to be used, particularly in certain clinical scenarios.

3. Potential generic competition: As patent expirations approach, the entry of generic versions of apixaban could impact ELIQUIS's market share and pricing[5].

Despite this competition, ELIQUIS is expected to maintain its strong market position:

Behind Keytruda in GlobalData's 2025 sales forecast are Bristol-Myers Squibb and Pfizer's Eliquis at $18.7 billion[9].

This projection underscores the continued confidence in ELIQUIS's market performance.

Challenges and Opportunities

As with any pharmaceutical product, ELIQUIS faces both challenges and opportunities in the coming years:

Challenges

1. Patent expiration: The potential entry of generic versions of apixaban could impact ELIQUIS's market share and pricing.

2. Regulatory pressures: Government initiatives to control drug prices, such as the Inflation Reduction Act in the U.S., may affect ELIQUIS's pricing and profitability[2].

3. Safety concerns: While ELIQUIS has a favorable safety profile, ongoing monitoring for adverse effects is crucial.

Opportunities

1. Expansion into emerging markets: There's significant potential for growth in regions with developing healthcare systems.

2. New indications: Ongoing research may uncover additional therapeutic applications for ELIQUIS, expanding its market reach.

3. Patient education initiatives: Increasing awareness about VTE and the importance of anticoagulation therapy could drive demand for ELIQUIS.

Future Outlook

The future of ELIQUIS in the DVT-PE treatment market looks promising, despite potential challenges. Key factors shaping its outlook include:

1. Continued research and development: Bristol Myers Squibb and Pfizer are likely to invest in further studies to expand ELIQUIS's indications and improve its efficacy.

2. Technological advancements: Integration of artificial intelligence and data analytics in anticoagulant therapy could enhance patient outcomes and drive ELIQUIS adoption[7].

3. Focus on patient adherence: Development of patient education and adherence programs could improve treatment outcomes and boost ELIQUIS's market position[5].

4. Global market expansion: As healthcare systems in emerging markets evolve, ELIQUIS is poised to capture new growth opportunities.

Key Takeaways

1. ELIQUIS has established itself as a leading anticoagulant for DVT-PE treatment, with a market value of USD 31.04 Billion in 2023.

2. The ELIQUIS market is projected to reach USD 75.53 Billion by 2031, growing at a CAGR of 9.3%.

3. Government regulations will impact ELIQUIS pricing, with a maximum fair price of $231.00 for a 30-day supply set to take effect in 2026 for Medicare patients.

4. North America remains the largest market for ELIQUIS, with significant growth potential in the Asia-Pacific region.

5. Despite challenges such as potential generic competition and regulatory pressures, ELIQUIS is expected to maintain its strong market position.

6. Future growth opportunities include expansion into emerging markets, new indications, and technological advancements in anticoagulant therapy.

FAQs

1. What is ELIQUIS used for? ELIQUIS (apixaban) is primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

2. How does ELIQUIS compare to other anticoagulants? ELIQUIS is a novel oral anticoagulant (NOAC) that offers several advantages over traditional anticoagulants like warfarin, including no need for routine blood monitoring, fewer drug interactions, and a lower risk of major bleeding events.

3. What is the projected market size for ELIQUIS by 2031? According to market projections, the ELIQUIS market is expected to reach USD 75.53 Billion by 2031, growing at a CAGR of 9.3% from 2024 to 2031.

4. How will government regulations affect ELIQUIS pricing? The U.S. Department of Health and Human Services has set a maximum fair price of $231.00 for a 30-day supply of ELIQUIS, which will take effect for Medicare patients on January 1, 2026.

5. What are the main factors driving the growth of the ELIQUIS market? Key growth drivers include the increasing prevalence of venous thromboembolism, expanding indications for ELIQUIS, growing awareness and diagnosis of related conditions, and the drug's favorable efficacy and safety profile compared to traditional anticoagulants.

Sources cited: [1] [2] [3] [4] [5] [6] [7] [9]